Targeting macrophage-myofibroblast transition with Caulis spatholobi to attenuate renal interstitial fibrosis: integrated UHPLC-Q-Exactive Orbitrap-MS, network pharmacology, and experimental validation
Our study is expected to provide the pharmacological mechanisms by which CS may be a promising anti-RIF drug for future clinical trials.
Authors
- Zhujiang Zhang
- Yixuan Chen (ORCID: https://orcid.org/0009-0005-8902-8142)
- Kexin Ren
- Yijing Cheng (ORCID: https://orcid.org/0000-0002-8294-1781)
- Tianjiao Ren
- Ziyi Song
- Yunlong Zhang (ORCID: https://orcid.org/0000-0002-2447-9138)
- Chao Yang (ORCID: https://orcid.org/0009-0001-2472-1393)
- Yan Lin
- Xue Li (ORCID: https://orcid.org/0000-0003-2485-4812)
Institutions
- Qiqihar University (CN)
- Qiqihar Institute of Engineering (CN)
- Qiqihar Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-10-09
- DOI
- https://doi.org/10.3389/fphar.2025.1649902
- Primary Topic
- Chronic Kidney Disease and Diabetes
- Type
- article
- Field-Weighted Citation Impact
- 0.00